首页> 外文期刊>Advances in Microbiology >Clinical Utility of Molecular Diagnosis of Blood Stream Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Hematologic Malignancies
【24h】

Clinical Utility of Molecular Diagnosis of Blood Stream Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Hematologic Malignancies

机译:异基因造血干细胞移植患者血液恶性肿瘤血流感染分子诊断的临床应用

获取原文
       

摘要

Blood stream infections (BSIs) are a serious problem in patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation (ASCT). We evaluated the clinical utility of molecular diagnosis for the management of BSIs in such patients. We prospectively performed a polymerase chain reaction (PCR) analysis of microbial DNA in blood samples from 10 consecutive patients with hematological malignancies at least once a week for one month after ASCT. In total, 51 and 54 samples were analyzed by bacterial and fungal PCR assays, respectively. Bacteria were detected in 24 samples from 8 patients by PCR, but in only 2 samples from one patient by blood culture. Notably, the bacteria detected in at least half of the 24 samples were considered to have originated from the oral cavity. Fungi were detected in 5 samples from 3 patients by PCR, but not by blood culture. Most cases with positive PCR results were manageable with empirical antimicrobial therapy without disclosure of DNA data. Our DNA analyses did not directly contribute to management of BSIs, but did provide valuable microbiological evidence for the patients. Additionally, oral management appears to require a critical re-evaluation to reduce the occurrence of BSIs in ASCT recipients.
机译:在接受异基因造血干细胞移植(ASCT)的血液系统恶性肿瘤患者中,血流感染(BSI)是一个严重的问题。我们评估了分子诊断在此类患者中管理BSI的临床效用。我们前瞻性地对10例连续的血液系统恶性肿瘤患者血液样本中的微生物DNA进行了聚合酶链反应(PCR)分析,在ASCT后的一个月内至少每周一次。总共分别通过细菌和真菌PCR分析了51个和54个样品。通过PCR在8个患者的24个样本中检测到细菌,而通过血液培养仅在1个患者的2个样本中检测到细菌。值得注意的是,在24个样本中至少有一半检测到的细菌被认为是源自口腔。通过PCR检出3例患者的5个样品中的真菌,但未通过血液培养检出。大多数具有阳性PCR结果的病例都可以通过经验性抗微生物治疗来治疗,而无需披露DNA数据。我们的DNA分析并没有直接有助于BSI的管理,但确实为患者提供了有价值的微生物证据。此外,口服治疗似乎需要进行严格的重新评估,以减少ASCT接受者中BSI的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号